USRE40246EExpiredUtilityPatentIndex 50
Method for the suppression of viral growth
Est. expirySep 30, 2014(expired)· nominal 20-yr term from priority
A61K 31/05A61K 31/09C07C 69/017C07C 43/23A61K 31/085A61K 31/222A61P 31/18A61P 31/12A61P 37/00
50
PatentIndex Score
0
Cited by
30
References
37
Claims
Abstract
A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of HO—, CH 3 O— and CH 3 (C═O) O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.
Claims
exact text as granted — not AI-modified1. A method for suppressing viral growth in a host which consists essentially of administering to the host an effective viral growth suppressing amount of a composition consisting essentially of a compound of the formula:
wherein R 1 , R 2 , R 3 and R 4 are each selected from the group consisting of HO—, CH 3 O— and CH 3 (C═O)O—, provided that R 1 , R 2 , R 3 and R 4 are not each HO—.
2. The method of claim 1 4 , wherein said compound is the water-soluble substituent is —O( C═O ) CH 2 NH ( CH 3 ) 2 .Cl .
3. The method of claim 1 for suppressing 4 , wherein the host is infected with Herpes simplex virus in the host .
4. A method for suppressing viral growth in a host infected with a virus comprising ( a ) providing a composition comprising a substantially purified compound and ( b ) administering said composition to the host in a dosage having an effective amount of the compound to suppress viral growth, wherein the compound is a derivative of nordihydroguaiaretic acid ( NDGA ) having the formula:
wherein R 1 , R 2 , R 3 and R 4 are each selected from the group consisting of HO—, CH 3 O— and CH 3 ( C═ ) O—, or a water soluble substituent, provided that R 1 , R 2 , R 3 and R 4 are not each HO—, wherein the water soluble substituent is selected from the group consisting of: —O ( C═O ) CH 2 NH ( CH 3 ) 2 .Cl, —O ( C═O ) CH 2 NH 2 ,
5. The method of claim 4 , wherein the water- soluble substituent is —O ( C═O ) CH 2 NH 2 .
6. The method of claim 4 , wherein the compound inhibits viral transcription.
7. The method of claim 4 , wherein the compound inhibits transactivation of viral gene.
8. The method of claim 4 , wherein the compound is 1 -( 3 , 4 - dihydroxyphenyl )- 4 -( 3 - hydroxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 4 - O - methyl - NDGA ).
9. The method of claim 4 , wherein the compound is 1 -( 3 , 4 - dihydroxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 - O - methyl - 4 - O - acetyl - NDGA ).
10. The method of claim 4 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 , 4 - dimethoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 3 ′, 4 - tri - O - methyl - NDGA ).
11. The method of claim 4 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 , 4 - dimethoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 4 , 4 ′ - tri - O - methyl - NDGA ).
12. The method of claim 4 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 - acetoxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 3 ′, 4 - di - O - methyl - 3 - O - acetyl - NDGA ).
13. The method of claim 4 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 3 ′ - di - O - methyl - 4 - O - acetyl - NDGA ).
14. The method of claim 4 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 - acetoxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 4 , 4 ′ - di - O - methyl - 3 - O - acetyl - NDGA ).
15. The method of claim 4 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 4 ′ - di - O - methyl - 4 - O - acetyl - NDGA ).
16. The method of claim 4 , wherein R 1 , R 2 , R 3 and R 4 are not each CH 3 O— or CH 3 ( C═O ) O— simultaneously.
17. The method of claim 4 , wherein the effective viral growth suppressing amount of the compound is less than 95 μM.
18. The method of claim 4 , wherein the effective viral growth suppressing amount of the compound is less than 62 . 7 μM.
19. The method of claim 4 , wherein the effective viral growth suppressing amount of the compound is less than 31 . 3 μM.
20. The method of claim 4 , wherein the effective viral growth suppressing amount of the compound is less than 25 μM.
21. The method of claim 4 , wherein the effective viral growth suppressing amount of the compound is less than 9 . 5 μM.
22. A method of inhibiting replication of an acyclovir- resistant virus in a cell comprising the steps of: ( a ) providing a substantially purified compound having a formula:
wherein R 1 , R 2 , R 3 and R 4 are each selected from the group consisting of HO—, CH 3 O— and CH 3 ( C═O ) O—, and a water soluble substituent, wherein the water soluble substituent is selected from the group consisting of: —O ( C═O ) CH 2 NH ( CH 3 ) 2 .Cl, —O ( C═O ) CH 2 NH 2 ,
( b ) contacting the cell with the compound.
23. A method of treatment of acyclovir- resistant viral infection in a subject comprising the steps of: ( a ) providing a substantially purified compound having the formula:
wherein R 1 , R 2 , R 3 and R 4 are each selected from the group consisting of HO—, CH 3 O— and CH 3 ( C═O ) O—, and a water soluble substituent, wherein the water soluble substituent is selected from the group consisting of: —O ( C═O ) CH 2 NH ( CH 3 ) 2 .Cl, —O ( C═O ) CH 2 NH 2 ,
( b ) administering the substantially purified compound to the subject.
24. A method of treatment of a subject infected with a virus, wherein the virus is resistant to acyclovir comprising the steps of:
( a ) providing a composition comprising a substantially purified compound; and ( b ) administering said composition in a dosage having a therapeutically effective amount of the compound to the subject, wherein the compound has the formula:
wherein R 1 , R 2 , R 3 and R 4 are each selected from the group consisting of HO—, CH 3 O— and CH 3 ( C═O ) O—, and a water soluble substituent, wherein the water soluble substituent is selected from the group consisting of: —O ( C═O ) CH 2 NH ( CH 3 ) 2 .Cl, —O ( C═O ) CH 2 NH 2 ,
25. The method of claim 24 , wherein the water- soluble substituent is —O ( C═O ) CH 2 NH 2 .
26. The method of claim 24 , wherein the water- soluble substituent is —O ( C═O ) CH 2 NH ( CH 3 ) 2 .Cl.
27. The method of claim 24 , wherein the compound inhibits viral transcription.
28. The method of claim 24 , wherein the compound inhibits transactivation of the viral gene.
29. The method of claim 24 , wherein the compound is 1 -( 3 , 4 - dihydroxyphenyl )- 4 -( 3 - hydroxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 4 - O - methyl - NDGA ).
30. The method of claim 24 , wherein the compound is 1 -( 3 , 4 - dihydroxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 - O - methyl - 4 - O - acetyl - NDGA ).
31. The method of claim 24 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 , 4 - dimethoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 3 ′, 4 - tri - O - methyl - NDGA ).
32. The method of claim 24 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 , 4 - dimethoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 4 , 4 ′ - tri - O - methyl - NDGA ).
33. The method of claim 24 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 - acetoxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 3 ′, 4 - di - O - methyl - 3 - O - acetyl - NDGA ).
34. The method of claim 24 , wherein the compound is 1 -( 3 - methoxy - 4 - hydroxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 3 ′ - di - O - methyl - 4 - O - acetyl - NDGA ).
35. The method of claim 24 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 - acetoxy - 4 - methoxyphenyl )- 2 , 3 - dimethylbutane ( 4 , 4 ′ - di - O - methyl - 3 - O - acetyl - NDGA ).
36. The method of claim 24 , wherein the compound is 1 -( 3 - hydroxy - 4 - methoxyphenyl )- 4 -( 3 - methoxy - 4 - acetoxyphenyl )- 2 , 3 - dimethylbutane ( 3 , 4 ′ - di - O - methyl - 4 - O - acetyl - NDGA ).
37. A method of treatment of viral infection in a host comprising the steps of: ( a ) providing a composition comprising a compound; and ( b ) administering said composition in a dosage having a viral inhibitory amount of the compound to the host, wherein the compound has the formula selected from the group consisting of:Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.